Physician profile
William E Aufox
NPI 1790740991
$494.96
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $67.58 · 2021: $91.85 · 2022: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $102.82 | 2022 | |
| Pfizer INC. | $75.96 | 2019-2020 | |
| Amgen INC. | $73.98 | 2019 | |
| Abbvie INC. | $71.81 | 2021 | |
| Novo Nordisk INC | $63.70 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $20.04 | 2021 | |
| Medtronic Vascular, INC. | $18.83 | 2019 | |
| Allergan, INC. | $18.16 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.55 | 2019 | |
| Flowonix Medical Incorporated | $11.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.43 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Aufox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.